FDA Grants Full Approval to Afami-Cel for Synovial Sarcoma and Expands Use to Adolescents
The U.S. Food and Drug Administration (FDA) has granted full approval to afamitresgene autoleucel, commercially known as Tecelra and also referred to as afami-cel, for the treatment of synovial…
Read the full articleYou might also wanna read
FDA Grants Traditional Approval to Selpercatinib for RET-Fusion Solid ...
The FDA has granted traditional approval to selpercatinib for adult and pediatric patients with RET fusion-positive solid tumors post-progre
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced ...
The FDA has granted traditional approval to selpercatinib (Retevmo) for the treatment of adult and pediatric patients 2 years of age and old
Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US ...
The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-c
FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma
FDA approved Sarclisa Escena (isatuximab-irfc), a subcutaneous formulation of Sanofi's Sarclisa, for the treatment of multiple myeloma acros
FDA Grants Traditional Approval to Retevmo for RET Fusion-Positive ...
The Food and Drug Administration (FDA) on July 14, 2026, granted traditional approval to Retevmo (selpercatinib) for adults and children 2 y
FDA approves Sanofi drug delivered with Enable on-body device
Sanofi announced today that the FDA approved the delivery of its Sarclisa anticancer therapy through the Enable Injections on-body device. S
Comments
Sign in to join the conversation.
No comments yet. Be the first.